MTOR and cholangiocarcinoma: Mechanistically, the mTOR inhibitor rapamycin inhibits the EMT, stem-like capacity, and migration of cholangiocarcinoma in vitro and inhibits the FBXW7 silencing-induced metastasis of these cells in vivo.